US · Healthcare · Biotechnology
EPS came in at -0.62 against a street estimate of -0.67 — a beat of 7.5%.
Analysts rate Monopar Therapeutics Inc a strong buy (11 buy, 1 hold, 0 sell out of 12) with an average price target of $129.92.
| Fund | Stake |
|---|---|
| HHG PLC | 19.63% |
| Jupiter Topco LLC | 19.55% |
| RA Capital Management, LLC | 9.94% |
| BlackRock Inc | 5.20% |
| Deerfield Management Co | 4.82% |
| Saturn V Capital Management LLC | 4.65% |
| Siren, L.L.C. | 4.02% |
| ADAR1 Capital Management LLC | 3.24% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 MONOPAR THERAPEUTICS INC. - Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash & Investments: $52.8 million cash + $81.5 million investments = $134.3 | 2026-08-12 |
| Results announced · Q3 2026 MONOPAR THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash and investments: $134.3 million as of June 30, 2026 • Net loss Q2 2026: $5.3 | 2026-08-12 |
| Reg FD disclosure · Q3 2026 MONOPAR THERAPEUTICS INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Monopar Therapeutics Inc., ticker MNPR (Nasdaq Capital Market) • Headquarters: 1 | 2026-07-22 |
| Reg FD disclosure · Q2 2026 MONOPAR THERAPEUTICS INC. - 8-K SUMMARY (JUNE 30, 2026) HEADLINE NUMBERS • Company: Monopar Therapeutics Inc. (ticker: MNPR, Nasdaq Capital Market) | 2026-06-30 |
| Reg FD disclosure · Q2 2026 MONOPAR THERAPEUTICS INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Monopar Therapeutics Inc. (ticker: MNPR, Nasdaq Capital Market) • Stock par | 2026-06-26 |
| Quarterly report · Q1 2026 MONOPAR THERAPEUTICS INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $52.5 million as of March 31, 2026 (down from $61.8 million at De | 2026-05-14 |
| Proxy statement · Q2 2026 MONOPAR THERAPEUTICS INC. — PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of six directors to the Board (plurality | 2026-04-30 |
| Annual report FY2025 MONOPAR THERAPEUTICS INC. – 10-K SUMMARY HEADLINE NUMBERS • Company: Clinical-stage biopharmaceutical company developing therapies for Wilson diseas | 2026-03-27 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Monopar Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.